FDA: Page 11
-
Carl Court via Getty Images
PTC Duchenne drug approval set to be revoked in Europe
The EMA’s drugs committee again recommended rescinding an OK for Translarna, which was cleared in 2014 despite questions about its benefit.
By Ben Fidler • Jan. 26, 2024 -
Sarah Silbiger via Getty Images
At FDA meeting, experts wrestle with hurdles to developing preterm birth drugs
A workshop highlighted the lack of investment and inadequate understanding of what causes early births, making drug research more challenging.
By Delilah Alvarado • Jan. 25, 2024 -
FDA orders new cancer warnings for CAR-T therapies
The agency later modified its warning for Gilead's Tecartus, tweaking the label's language to reflect the fact that none of T cell malignancies in question had occurred in Tecartus-treated patients.
By Jonathan Gardner • Updated Jan. 24, 2024 -
Mario Tama / Getty via Getty Images
FDA says no ‘clear relationship’ between GLP-1 drugs and suicide risk
Regulators will continue to evaluate suicide ideation as the data don't "definitively rule out" an association.
By Jonathan Gardner • Jan. 12, 2024 -
Getty Images
FDA authorizes Florida to import drugs from Canada
The clearance is a major shift for the agency, which described its decision as a “first step” in allowing Florida to bulk purchase lower-cost Canadian medicines.
By Jonathan Gardner , Ned Pagliarulo • Jan. 5, 2024 -
Yujin Kim / MedTech Dive, original photo courtesy of U.S. Food and Drug Administration
5 FDA decisions to watch in the first quarter
The agency could soon issue verdicts on new drugs from Eli Lilly and Merck, as well as on what could be the first TIL therapy.
By Ben Fidler , Ned Pagliarulo • Jan. 4, 2024 -
FDA
FDA ends busy year with three drug rejections
Amgen had its bid for full approval of the cancer drug Lumakras turned back by the agency, which also issued complete response letters to Zealand Pharma and Merck & Co. in December.
By Jonathan Gardner • Jan. 2, 2024 -
Courtesy of Sarepta
Sarepta tests FDA flexibility with bid to expand Duchenne gene therapy’s approval
The biotech is asking the agency to clear its treatment Elevidys in more patients with the disease, despite a confirmatory trial that missed its main goal.
By Ned Pagliarulo • Dec. 22, 2023 -
Sara Silbiger via Getty Images
Ionis, Astrazeneca win FDA approval of competitor to Alnylam drug
The clearance of Wainua for transthyretin amyloidosis opens up a new front in a long-running commercial battle between Ionis and Alnylam.
By Ben Fidler • Dec. 22, 2023 -
Courtesy of Merck & Co.
Merck gets FDA decision date for new pneumococcal vaccine
The company’s shot targets 21 strains of pneumococcal bacteria and, if approved, would compete with Pfizer’s Prevnar 20.
By Delilah Alvarado • Dec. 19, 2023 -
FDA
FDA widens use of cancer drug Merck acquired for $1B
Welireg, which Merck got through its purchase of Peloton Therapeutics, can now be used to treat an advanced form of kidney cancer, adding to an earlier clearance in a rare genetic disease.
By Jonathan Gardner • Dec. 15, 2023 -
Carl Court via Getty Images
European regulators push Biogen, CRISPR drugs toward approval
While a positive recommendation for the gene editing treatment Casgevy was expected, a clearance for Biogen’s Skyclarys has been no sure bet.
By Ben Fidler • Dec. 15, 2023 -
Permission granted by Novartis
Novartis gets FDA approval of closely watched rare disease drug
The pharma is developing Fabhalta, now cleared for paroxysmal nocturnal hemoglobinuria, for several other rare, complement-driven diseases.
By Ned Pagliarulo • Dec. 6, 2023 -
Courtesy of Eli Lilly
Lilly cancer drug cleared by FDA for expanded leukemia, lymphoma use
Jaypirca, which has been on the market for less than a year, can now be used for more types of blood cancer but not as early as rival drugs from AbbVie and AstraZeneca.
By Jonathan Gardner • Dec. 4, 2023 -
shutterstock.com/DadBusiness
Sponsored by Target RWEOvercoming scalability challenges in real-world data processing for transformative patient care
Accurate and timely processing of data is imperative to create robust analytical datasets that can be used in the RWE setting.
By Rob Sullivan, Chief Data & Analytics Officer • Dec. 4, 2023 -
FDA names chief scientist Bumpus as Woodcock’s successor
Bumpus, a former Johns Hopkins professor, named “creating a new model” for the FDA’s Office of Regulatory Affairs as one of her priorities when she steps into the role next year.
By Jonathan Gardner • Nov. 29, 2023 -
Peddalanka Ramesh Babu via Getty Images
FDA investigating cancer risk linked to CAR-T cell therapy
Reports of T cell malignancies following treatment triggered the FDA’s alert. But the event appears rare, according to companies and physicians.
By Jonathan Gardner • Updated Nov. 28, 2023 -
Win McNamee via Getty Images
Top FDA official Woodcock to retire early next year
The 37-year veteran helmed the agency’s pandemic response, and was a key decision-maker in controversial calls on opioids, an Alzheimer's therapy and muscular dystrophy drugs.
By Jonathan Gardner • Updated Nov. 17, 2023 -
Getty Images
FDA approves new Bristol Myers drug for lung cancer
Acquired via a $4 billion biotech buyout, Augtyro is one of an array of new products the pharma hopes will offset patent expirations for current top sellers.
By Jonathan Gardner • Nov. 16, 2023 -
Valneva’s chikungunya vaccine approved by FDA
The preventive shot is the first to receive regulatory approval for the mosquito-borne illness, which is growing in prevalence worldwide.
By Delilah Alvarado • Nov. 10, 2023 -
Takeda secures FDA approval for colon cancer drug
The pharma paid $400 million to license the drug from Hutchmed earlier this year in an effort to bolster its oncology business.
By Delilah Alvarado • Nov. 9, 2023 -
Sarah Silbiger via Getty Images
Obesity drugsLilly rival to weight loss drug Wegovy approved by FDA
The pharmaceutical company will sell the GLP-1 drug, branded as Zepbound, at a list price about 20% lower than Novo Nordisk's competing therapy.
By Jonathan Gardner , Ned Pagliarulo • Updated Nov. 8, 2023 -
Sarah Silbiger via Getty Images
Vertex, CRISPR therapy for sickle cell passes FDA panel test
The high-profile meeting focused on the theoretical risks of CRISPR gene editing, as both the FDA and its advisory committee appeared convinced by the efficacy of the companies’ exa-cel treatment.
By Ned Pagliarulo • Oct. 31, 2023 -
Yujin Kim / MedTech Dive, original photo courtesy of U.S. Food and Drug Administration
A play-by-play of the FDA’s meeting on Vertex, CRISPR’s sickle cell therapy
Expert advisers dug deep on the risks of off-target gene editing and debated how best to set guidelines for the fast-growing field. Catch up on their full discussion here.
By Ned Pagliarulo , Jonathan Gardner , Gwendolyn Wu • Updated Oct. 31, 2023 -
Sarah Silbiger/Getty Images via Getty Images
FDA staff focus on ‘off-target’ risk in review of Vertex, CRISPR sickle cell therapy
Documents released ahead of a Tuesday advisory meeting show agency scientists to be generally convinced by the treatment’s benefit, a sign analysts read as positive.
By Ned Pagliarulo • Oct. 27, 2023
Previous
